Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-L19SIP (Radretumab) in Patients With Cancer
NCT01242943Phase 2Terminated
- Sponsor
- Philogen
- Start
- Nov 2008
- Primary completion
- Feb 2011
- Modality
- Antibody Fragments, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of 131I-radretumab in solid tumor, lung cancer, prostate cancer (PCa) and 1 more, sponsored by Philogen. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Antitumour activity. Started Nov 2008; status: terminated.
02
Drugs
131I-radretumab
03
Conditions
solid tumorlung cancerprostate cancer (PCa)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01242943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01242943.